A pharmaceutical company acquires a biotech startup and imposes its existing processes immediately without transition planning. The MOST likely outcome is:
-
A
Rapid integration and synergy realization
-
B
Loss of key talent and innovative culture from the acquired firm
-
C
Improved compliance and standardization
-
D
Faster time to market for new products